Harold Kim

Eligibility of monoclonal antibody-based therapy for patients with severe asthma: a Canadian cross-sectional perspective \textbar Allergy, Asthma & Clinical Immunology \textbar Full Text

The International/Canadian hereditary angioedema guideline

Betschel S, Binkley K, Borici-Mazi R, Chapdelaine H, Hébert J, Kanani A, Keith PK, Lacuesta G, Waserman S, Yang W

Canadian Thoracic Society guideline for the management of severe asthma in children, adolescents and adults

Côté A, Godbout K, Ramsey C, Lal A, Kim H, Yang CL, Samanta T, O’Keefe A, Mahdavian M, Radhakrishnan D

Would the number of new cases of hereditary angioedema decrease due to declining fertility rates?

Wong L, Kim H, Kuprowski M

Summarizing the 2024 immunotherapy manual of the Canadian society of allergy and clinical immunology

Bruton Joe A, Cai G, Nazarali S, Kim H, Lam G, Waserman S

Laying the foundation in food allergy education: CSACI food allergy educator program

Protudjer JLP, Mack DP, Connors L, Lidington J, Kim H

Evaluating the efficacy of a novel home-based oral food challenge protocol for pediatric food protein induced enterocolitis syndrome

Morris EG, Huan PW, Protudjer JLP, Li L, Rondilla N, Abraham J, Kim H

Non-Allergist Physician Algorithm for Prescribing Allergen Immunotherapy

Kaplan A, Waserman S, Mack D, Hauptman R, Ellis A, Mack L, Photopolous S, Ruiz J, Begin P, Micks T

Health-related quality of life in hereditary angioedema patients treated with subcutaneous C1 inhibitor (C1-INH) therapy in Canada

Waserman S, Lacuesta G, Kanani AS, Sussman GL, Kim H, Chapdelaine H, Goubran Messiha HA, Kalicinsky C, Adatia A, Yap B

Tezepelumab in patients with allergic and eosinophilic asthma

Caminati M, Buhl R, Corren J, Hanania NA, Kim H, Korn S, Lommatzsch M, Martin N, Matucci A, Nasser SM